Hcor utilises Oracle Clinical One for independent phase 3 immunology studies

Brazil's Hcor harnesses Oracle's cloud solutions to independently manage critical immunology trials, reducing costs and accelerating execution.

Brazil-based research organisation, Hcor, has taken a significant step by employing Oracle Clinical One Data Collection to advance its critical phase 3 immunology studies. Previously reliant on third-party firms, Hcor often faced added time and complexity in study builds. The transition to Oracle's modern, cloud-based data collection platform now allows Hcor to manage these studies autonomously resulting in reduced costs and accelerated trial execution.

Oracle Clinical One Data Collection, anchored on the security, performance, and scalability of Oracle Cloud Infrastructure, is part of the company's extensive life sciences solutions portfolio.

Hcor is not just a hospital specialising in cardiology, oncology, and other healthcare fields; it's also a renowned research institute recognised for its innovation and role in clinical trials. This partnership with Oracle is no exception. “With Oracle Clinical One Data Collection, we have built two important immunology trials independently using Oracle’s robust and reliable platform, which can help to accelerate potentially life-changing clinical trials,” said Research Institute Manager, Tamiris Abait Miranda.

Oracle's approach to electronic data capture offers life sciences organisations new ways to gather datasets from diverse sources. The system helps unlock valuable insights, freeing Hcor from third-party dependencies.

Recognised as an electronic data capture leader by the Everest Group PEAK Matrix, Oracle's platform excels with its intuitive, user-friendly design. It simplifies study builds and facilitates real-time adjustments, eliminating the need for costly programming or intervention. This capability not only expedites trial timelines but also helps cut down on build times.

"Our unified platform helps organisations like Hcor make it easier to build studies independently and have more flexibility and control throughout the entire trial lifecycle," said Seema Verma, Oracle executive vice president. She emphasised Oracle's mission of leveraging the latest AI and cloud technology to revolutionise study conduct, ensuring patient-centric solutions and accelerated regulatory submissions.

Additionally, Hcor benefits from Oracle Exadata Cloud@Customer’s low latency and high computing power. By transitioning its workloads, Hcor has boosted IT performance by 20%, with developers launching projects five times faster. The overhaul has significantly enhanced system security, project completion rates, and patient care efficiencies.

The collaboration between Hcor and Oracle showcases a transformative approach in clinical research, emphasising the importance of technology in driving healthcare innovation and patient-centric care.

Panasonic reveals ELEVATE, aiming to enhance its channel partner programme with tiered structures,...
The State of Application Strategy Report outlines AI’s progression into a production workload,...
Flexera's 2026 report reveals organisations struggle with cloud management amidst accelerated GenAI...
PowerStore Elite aims to address EMEA’s evolving storage needs amid accelerating data growth,...
Check Point’s 2026 report highlights the widening gap between AI-driven advancements and...
Westcon-Comstor has launched the SASEvolution programme across EMEA, combining technology from Palo...
New private cloud, storage, and data protection solutions simplify operations, strengthen...
Cybercrime in the financial sector has intensified, with AI posing new challenges. CrowdStrike...